Ligelizumab - Novartis

Drug Profile

Ligelizumab - Novartis

Alternative Names: QGE-031

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tanox
  • Developer Novartis
  • Class Allergens; Antiallergics; Antiasthmatics; Food allergy immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action IgE receptor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Atopic dermatitis; Bullous pemphigoid; Urticaria
  • No development reported Hypersensitivity

Most Recent Events

  • 09 Jul 2018 Novartis Pharmaceuticals plans a phase III trial for Urticaria in September 2018 , (NCT03580356)
  • 09 Jul 2018 Novartis Pharmaceuticals plans a phase III trial for Urticaria in September 2018 (NCT03580369)
  • 19 Feb 2018 Novartis plans a phase II trial for Urticaria (In adolescents, Adjunctive treatment) (NCT03437278)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top